Company intelligence / Profile preview
Galmed Pharmaceuticals
- Ownership
- Public · GLMD
- Employees
- ~6
- Development stage
- Phase 3
Overview
Galmed’s lead compound Aramchol has shown promising results in reducing markers of systemic inflammation and liver fibrosis in NASH patients. The company recently unveiled novel pharmacodynamic blood markers that may serve as early indicators of efficacy. Clinical trial data have driven recent market optimism and strategic partnerships with research hospitals. The company’s financials show improved liquidity but ongoing need for capital
- Therapeutic areas
- GastroenterologyCardiovascularImmunologyOncologyInfectious Diseases
- Modalities
- small molecules (notably synthetic fatty acid-bile acid conjugates)peptides
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Galmed Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galmed Pharmaceuticals.